Chemistry Reference
In-Depth Information
3. Feher M, Schmidt JM. Property distributions: differences between drugs, natural
products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci.
2003;43:218 - 227.
4. Ortholand J-Y, Ganesan A. Natural products and combinatorial chemistry: back to
the future. Curr. Opin. Chem. Biol. 2004;8:271 - 280.
5. Butler MS. The role of natural product chemistry in drug discovery. J. Nat. Prod.
2004;67:2141 - 2153.
6. Clardy J, Walsh C. Lessons from natural molecules. Nature 2004;432:829 - 837.
7. Nielsen J. Combinatorial synthesis of natural products. Curr. Opin. Cell. Biol.
2002;6:297 - 305.
8. Newman DJ, Cragg GM. Natural products as sources of drugs over the last 25 years.
J. Nat. Prod. 2007;70:461 - 477.
9. Noble RL, Beer CT, Cutts JH. Role of chance observation in chemotherapy:
Vinca
rosea
. Ann. N.Y. Acad. Sci. 1958;76:882 - 894.
10. Neuss N, Cone NJ, Gorman M, Boaz HE. Vinca alkaloids. II. Structures of
leurocristine (LCR) and vincaleukoblastine (VLB). J. Am. Chem. Soc. 1962;84:
1509 - 1510.
11. Svoboda GH. Alkaloids of
Vinca rosea
(
Catharanthus rosea
).9. Extraction and char-
acterization of leurosidine and leurocristine. Lloydia 1961;24:173 - 178.
12. Joel S. The comparative clinical pharmacology of vincristine and vindesine: Does
vindesine offer any advantage in clinical use? Cancer Treat. Rev. 1995;21:513 - 525.
13. Duflos A, Kruczynski A, Barret J-M. Novel aspects of natural and modified vinca
alkaloids. Curr. Med. Chem.: Anti-Cancer Agents 2002;2:55 - 70.
14. Gueritte F, Fahy J. The vinca alkaloids. In: Anticancer Agents from Natural Products.
Cragg GM, Kingston DGI, Newman DJ, eds. 2005. Taylor and Francis, Boca Raton,
FL. pp. 123 - 135.
15. Pettit GR, Cragg GM, Herald DL, Schmidt JM, Lohavanijaya P. Isolation and struc-
ture of combretastatin. Can. J. Chem. 1982;60:1374 - 1376.
16. Pinney KG, Jelinek C, Edvardsen K, Chaplin DJ, Pettit GR. The discovery and
development of the combretastatins. In: Anticancer Agents from Natural Products.
Cragg GM, Kingston DGI, Newman DJ, eds. 2005. Taylor and Francis, Boca Raton,
FL. pp. 23 - 46.
17. Zheng W, Seletsky BM, Palme MH, Lydon PJ, Singer LA, Chase CE, Lemelin CA,
Shen Y, Davis H, Tremblay L, et al. Macrocyclic ketone analogues of halichondrin
B. Bioorg. Med. Chem. Lett. 2004;14:5551 - 5554.
18. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA,
Wilson L. The primary antimitotic mechanism of action of the synthetic halichondrin
E7389 is suppression of microtubule growth. Mol. Cancer Ther. 2005;4:1086 - 1095.
19. Dabydeen DA, Burnett JC, Bai R, Verdier-Pinard P, Hickford SJ, Pettit GR, Blunt
JW, Munro MHG, Gussio R, Hamel E. Comparison of the activities of the truncated
halichondrin B analog NSC 707389 (E7389) with those of the parent compound and
a proposed binding site on tubulin. Mol. Pharmacol. 2006;70:1866 - 1875.
20. Bai R, Pettit GR, Hamel E. Binding of dolastatin-10 to tubulin at a distinct site for
peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
J. Biol. Chem. 1990;265:17141 - 17149.
